Business Context and Reporting Period
Company: Align Technology, Inc. (ALGN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Align Technology is a global leader in digital oral health, primarily known for its Invisalign clear aligner system and iTero intraoral scanning systems. The company operates through two reportable segments: Clear Aligner and Systems and Services.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $1,040.1 | $979.3 |
| Gross Profit | $736.6 | $680.1 |
| Gross Margin | 70.8% | 69.5% |
| Operating Income | $142.0 | $131.1 |
| Operating Margin | 13.6% | 13.4% |
| Net Income | $112.8 | $93.2 |
| Diluted EPS | $1.57 | $1.27 |
| Operating Cash Flow | $151.0 | $52.7 |
| Cash and Equivalents (End of Period) | $1,060.0 | $874.1 |
| Capital Expenditures | $30.8 | $25.3 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 6.2% year-over-year (YoY), driven by a 7.4% increase in Clear Aligner revenues and a 0.9% increase in Systems and Services revenues.
- Case Volume: Clear Aligner case volume rose 6.7% YoY to 685.7 thousand cases. Teen and growing patient shipments increased 4.8%.
- Legal Settlements: A significant one-time charge of $30.6 million was recorded for legal settlements in Q1 2026, compared to $4.2 million in Q1 2025.
- Restructuring: The company completed its 2025 restructuring plan, incurring total charges of approximately $41.6 million. $6.3 million remained unpaid as of March 31, 2026.
- Asset Disposal: The company recognized an $11.7 million gain on assets held for sale (a manufacturing facility in Mexico) due to an increase in fair value.
- Investments: The company made a $50.0 million additional investment in Heartland Dental Holding Corporation and recorded a $7.7 million fair value adjustment gain on this investment.
- Stock Repurchases: The company repurchased approximately $31.2 million of common stock in Q1 2026. $800.0 million remains available under the April 2025 Repurchase Program.
Guidance, Outlook, and Risks
- Capital Expenditure Guidance: Management expects fiscal year 2026 capital expenditures to range between $125 million and $150 million.
- Repurchase Outlook: The company expects to repurchase up to $200 million of common stock over the six-month period beginning May 1, 2026.
- Macroeconomic Risks: Management cites ongoing macroeconomic challenges, including inflation, higher interest rates, and geopolitical tensions (specifically conflicts in the Middle East and Ukraine), as factors that may dampen consumer sentiment and demand for elective dental procedures.
- Legal Proceedings: Significant ongoing litigation includes antitrust class actions (appeals pending), patent infringement suits against Straumann (trial set for June 2026), and extensive global IP litigation against Angelalign (including a preliminary injunction obtained in Europe and an ITC investigation in the U.S.).
- Tax Matters: A statutory appeal regarding UK VAT on clear aligners is pending before the Upper Tribunal, with a hearing scheduled for May 2026. The outcome remains uncertain.
Investor Verification Checklist
- Legal Settlement Impact: Verify the nature and finality of the $30.6 million legal settlement charge and potential for future related liabilities.
- Geopolitical Exposure: Assess the potential impact of the U.S.-Iran conflict and Middle East instability on supply chains, particularly regarding manufacturing in Mexico and operations in Israel.
- UK VAT Appeal: Monitor the May 2026 Upper Tribunal hearing regarding the VAT exemption for clear aligners, which could impact future tax provisions.
- Competitive Landscape: Review the status of the ITC investigation against Angelalign and the outcome of the Straumann patent trial scheduled for June 2026.
- Case Volume Trends: Confirm if the 6.7% growth in case volume is sustainable given the noted macroeconomic headwinds and potential shift to lower-priced products.